We are live on ! Find out more

DataMeds AI

MEDS

Market cap $9.9M

2.19 USD

+0.13

6.31%

At close Updated Oct 28, 2:42 PM EDT

1 day

6.31%

5 days

-17.36%

1 month

-42.52%

3 months

-38.31%

6 months

-61.91%

Year to date

-89.9%

1 year

-93.26%

5 years

-98.85%

10 years

-98.85%

About: DataMEDS AI Inc is a healthcare technology and pharmaceutical logistics company. The group simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. Its solutions provide a single, integrated platform for pharmacies, wholesale distribution, and a fulfillment network focused on Independent Pharmacies and Specialty Lite medications.

Healthcare Medical Distribution

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 15.4%

Neutral 84.6%

Negative 0%

DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network

Being marketed to 6,500+ Corexa Health Pharmacy Network of independent pharmacies To be launched first at Corexa Pharmacy in Lakeland, FL retail location in Q4/2026 Program will aim to bring best practices for respiratory season to community pharmacies Nuvaxovid COVID vaccine (protein-based / non-mRNA) prioritized for campaign rollout Improve telehealth availability in the pharmacy through Health Lives Here mobile app Tests to include COVID neutralizing antibodies, antibodies & acute respiratory infections Long COVID-related biomarkers (cardiovascular, incl microclots; immune; metabolic; etc) Immune profiling for other circulating respiratory diseases (influence, RSV, strep, others) Improve access to FDA-approved antivirals Pharmacist education on Tollo Health medical foods and dietary supplements TAMPA, FL / ACCESS Newswire / October 23, 2026 / DataMEDS AI, Inc. ("DataMeds SI," "DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform, today announced that it has established a "Health Lives Here" Community Respiratory Program ("HLH CRP") that will be marketed to the 6,500+ independent pharmacies in the Corexa Health Pharmacy Network. The aim of HLH CRP is to bring respiratory season best practices to community pharmacies and improve access to protein-based vaccines, diagnostics and therapeutics targeting respiratory infectious diseases as cold and flu season begins across the U.S. Corexa Pharmacy in Lakeland, Florida will be the first pharmacy to roll out the program later in the fourth quarter of 2026.

DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network

Datavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology License

PHILADELPHIA--(BUSINESS WIRE)--Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and real-world asset (“RWA”) tokenization, today announced that it has entered into a non-binding letter of intent (“LOI”) to acquire a 19.9% equity interest in DataMEDS AI, Inc. (NASDAQ: MEDS) (“DataMEDS”) in consideration of an expansion of its existing technology license with DataMEDS. The proposed t.

Datavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology License

DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies

Proprietary IP Position Until At Least 2042 to Enable Consolidation of Infrastructure targeting market expected to grow from $9.6 billion in 2025 to $93.4 billion in 2035 Customer Acquisition Plan Leverages Existing Relationship with NFL Alumni Health Final Guidance issued by FDA Provides Roadmap for Prescription Drug Proprietary Health Lives Here™ App and DelivMeds® Software Network of 6,500 Pharmacies to Provide Nationwide Physical Healthcare Outlet TAMPA, FL / ACCESS Newswire / October 22, 2026 / DataMEDS AI, Inc. ("DataMeds SI," "DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform, today announced that it has entered into an amended and restated non-binding letter of intent dated October 19, 2026 ("LOI") with Datavault AI Inc . ("Datavault AI") (NASDAQ:DVLT), Data Health Partners, Inc.'s ("DHP") wholly-owned subsidiary REBOOT Health AI, Inc., EOS Technology Holdings, Inc. ("EOS"), Scilex Holding Company ("Scilex") (NASDAQ:SCLX) and HealthBridge Advisors, LLC ("HealthBridge Advisors").

DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies

DataMeds Regains Compliance With NASDAQ Listing Standards

TAMPA, FL / ACCESS Newswire / October 20, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence (artificial intelligence) platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has received a notification letter (the "Compliance Notice") from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC ("Nasdaq") dated October 19, 2026, informing DataMEDS that it has regained compliance with Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule"). In order to regain compliance with the Equity Rule, DataMEDS needed to have a minimum stockholders' equity of $2.5 million.

DataMeds Regains Compliance With NASDAQ Listing Standards

DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap

Corexa Health's three divisions - pharmacy, distribution, and tech & hub - positioned to serve the emerging compounded peptide market TAMPA, FL / ACCESS Newswire / October 16, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today applauded the issuance of a new policy proposal by the U.S. Food and Drug Administration (FDA) entitled "Interim Access Policy for Compounding Using Certain Peptides." The new proposed policy comes less than three months following the recommendation from FDA's Pharmacy Compounding Advisory Committee (PCAC) to loosen restrictions on the use of six peptides.

DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap

DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform

Platform to be integrated into Health Lives Here app as a subscription offering TAMPA, FL / ACCESS Newswire / October 14, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has entered into an exclusive license, revenue sharing and marketing agreement with REBOOT Health AI, Inc. ("REBOOT") for Direct-to-Consumer (DTC) rights in the United States to REBOOT's proprietary care management platform. The Companies will work together to tailor the platform for use in the Health Lives Here mobile application for patients taking GLP-1 receptor agonist medications (the "GLP Management Platform") leveraging the patents and patent applications (the "IP") under the license.

DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform

DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division

Leading Health IT Company has Implemented Cost Control Measures and Refocused Remaining Workforce Towards ChemoFx® Commercialization with Hospital Systems, HMOs, GPOs and Cancer Centers TAMPA, FL / ACCESS Newswire / October 13, 2026 / DataMeds AI, Inc . (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has implemented cost control measures, primarily through reductions in corporate management positions, to focus the workforce spend on commercializing ChemoFx® as a diagnostic lab test to help oncologists inform their chemotherapy regimen selection, initially for gynecologic cancers only.

DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division

DataMeds AI Stock Rises After Humana Adds Medicaid Coverage for ChemoFx Cancer Test

DataMeds AI, Inc. (NASDAQ:MEDS) shares are up on Monday as traders react to Medicaid coverage policy news tied to the company's Helomics business and its ChemoFx assay.

DataMeds AI Stock Rises After Humana Adds Medicaid Coverage for ChemoFx Cancer Test

DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx(R) Assay In Gynecologic Cancers

Humana adds ChemoFx® to its Medicaid Pharmacogenomics Testing coverage policy TAMPA, FL / ACCESS Newswire / October 12, 2026 / DataMeds AI, Inc . (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company vertically integrating its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that its recently acquired CLIA-certified precision oncology laboratory subsidiary Helomics Corporation has received a Medicaid coverage determination in gynecologic cancers for the ChemoFx® Assay, a commercially available chemoresponse test that measures how a patient's live tumor cells respond to chemotherapy agents, in gynecologic cancers.

DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx(R) Assay In Gynecologic Cancers

Datameds AI Files DBAs Datameds SI And Corexa Health SI And Reminds Shareholders Of Record As Of August 7, 2026 Of Dream Bowl Meme Coin I Payment

Healthcare IT Company and its Subsidiary Undertake Action Following US Government's Updated Nomenclature TAMPA, FL / ACCESS Newswire / October 5, 2026 / DataMeds AI, Inc . (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its artificial intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has filed DBAs for ‘DataMEDS SI' and ‘Corexa Health SI'.

Datameds AI Files DBAs Datameds SI And Corexa Health SI And Reminds Shareholders Of Record As Of August 7, 2026 Of Dream Bowl Meme Coin I Payment

See News Rankings

Price charts implemented using Lightweight Charts™